Australia markets closed
  • ALL ORDS

    7,255.80
    +16.40 (+0.23%)
     
  • AUD/USD

    0.7752
    -0.0033 (-0.42%)
     
  • ASX 200

    7,023.60
    +9.40 (+0.13%)
     
  • OIL

    65.31
    -0.06 (-0.09%)
     
  • GOLD

    1,850.00
    +11.90 (+0.65%)
     
  • BTC-AUD

    57,467.42
    -6,894.61 (-10.71%)
     
  • CMC Crypto 200

    1,238.12
    -120.44 (-8.87%)
     

BIOQUAL Presents Unaudited Financial Results for Third Quarter of Fiscal Year 2021

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
  • Oops!
    Something went wrong.
    Please try again later.

BIOQUAL, Inc. (OTC-Pink:BIOQ) (www.bioqual.com):

Nine Months Ended

Three Months Ended

February 28,

February 29,

February 28,

February 29,

2021

2020

2021

2020

Revenue

$

41,070,486

$

32,884,055

$

12,584,303

$

11,593,217

Income Before Income Tax

$

5,942,062

$

4,150,830

$

1,379,460

$

1,018,306

Net Income

$

4,203,962

$

2,936,730

$

975,960

$

720,406

Basic Earnings per Share

of Common Stock

$

4.70

$

3.29

$

1.09

$

.81

Diluted Earnings per Share

of Common Stock

$

4.70

$

3.29

$

1.09

$

.81

Weighted Average

Number of Shares Outstanding

For Basic Earnings Per Share

893,932

893,416

894,416

893,416

Weighted Average

Number of Shares Outstanding

For Diluted Earnings Per Share

893,932

893,843

894,416

893,843

For more detail related to the fiscal year 2021 unaudited third quarter results, please visit our web site at www.bioqual.com.

Statements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors including risks relating to the ability to continue to extend current government contracts; the Company’s ability to obtain new government or commercial contracts; continued demand for the use of animal models in scientific research; the Company’s ability to perform under its contracts in accordance with the requirements of the contracts; the actual costs incurred in performing the Company’s contracts and its ability to manage its costs, including its capital expenditures; dependence on third parties; future capital needs; the ability to fund its capital needs through the use of its cash on hand and line of credit; and the future availability and cost of financing/capital sources to the Company.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005716/en/

Contacts

Mark G. Lewis, Ph.D., CEO (240-404-7654)